Gene Therapy in the Neuroendocrine System


Institute for Biochemical Research-Histology B, Faculty of Medicine, National University of La Plata, La Plata, Argentina

Abstract

The implementation of experimental gene therapy in animal models of neuroendocrine diseases is an area of growing interest. In the hypothalamus, restorative gene therapy has been successfully implemented in Brattleboro rats, an arginine vasopressin (AVP) mutant which suffers from diabetes insipidus, and in Koletsky (fa<sup>b</sup>/fa<sup>b</sup>) and in Zucker (fa/fa) rats which have leptin receptor mutations that render them obese, hyperphagic and hyperinsulinemic. In the above models, viral vectors expressing AVP, leptin receptor b and proopiomelanocortin, respectively, were stereotaxically injected in the relevant hypothalamic regions. In rats, aging brings about a progressive degeneration and loss of hypothalamic tuberoinfundibular dopaminergic (TIDA) neurons, which are involved in the tonic inhibitory control of prolactin secretion and lactotropic cell proliferation. Stereotaxic injection of an adenoviral vector expressing insulin-like growth factor I corrected their chronic hyperprolactinemia and restored TIDA neuron numbers. Spontaneous intermediate lobe pituitary tumors in a retinoblastoma (Rb) gene mutant mouse were corrected by injection of an adenoviral vector expressing the human Rb cDNA and experimental prolactinomas in rats were partially reduced by intrapituitary injection of an adenoviral vector expressing the HSV1-thymidine kinase suicide gene. These results suggest that further implementation of gene therapy strategies in neuroendocrine models may be highly rewarding.

Gene therapy, the transfer of genetic material for therapeutic purposes, has undergone an explosive development in the last decade. Current molecular biology technology has made it possible to consider as feasible genetic manipulations that would have been deemed utopic not too long ago. Particularly important advances are being made in the improvement of gene transfer technology. Current efforts for the development of more efficient viral vectors focus
on two main objectives, namely the achievement of cell-type specificity for transgene delivery and the design of vectors where, once the transgene is incorporated into the target cell, its expression can be regulated by small molecules.

Gene transfer to the central nervous system (CNS) poses significant challenges due to both the relative inaccessibility of the brain and spinal cord and the extraordinary complexity of CNS structures. On the other hand, this approach offers unique advantages for the effective delivery of therapeutic molecules to specific CNS regions affected by tumors, neurodegenerative processes or genetic defects.

Although a great deal of research efforts are been devoted to developing gene therapy strategies for neurological diseases [1], most of the work has been done in non-diencephalic brain regions. Much less work has been performed in the neuroendocrine system despite the unique advantages that it offers for the assessment of in vivo gene therapy strategies. In this article we will evidence these advantages by reviewing the core of documented studies in which in vivo gene therapy has been implemented in the neuroendocrine system of rodent models.

**In vivo Gene Therapy in the Hypothalamus**

*Brattleboro Rat*

The first animal model in which gene therapy was implemented in the hypothalamus was the Brattleboro rat. This mutant contains a single basepair mutation in the arginine vasopressin (AVP) gene which results in a highly conspicuous diabetes insipidus (DI) phenotype characterized by the production of large volumes of hypo-osmotic urine and compensatory polydipsia [2]. An adenoviral vector (AdAVP) encoding the rat AVP cDNA under the control of the cytomegalovirus (CMV) promoter was used in this animal model. When AdAVP was stereotaxically injected into the substantia innominata (a non-AVP producing hypothalamic area) of normal Wistar-Kyoto rats, expression of AVP mRNA was detected from 7 days to 6 months postinjection [3]. Injection of AdAVP into the supraoptic nucleus (SON, where part of the magnocellular neurons that produce AVP in normal animals lie) of Brattleboro rats resulted in substantial expression of AVP in magnocellular cells as well as in the presence of immunohistochemically detectable AVP in their axons projecting to the posterior pituitary. Measurement of urine output and urine osmolality showed that the symptoms of DI in the Brattleboro rats were significantly reduced for up to 4 months after injection of the viral vector [3]. An equine infectious anemia viral (EIAV) vector expressing AVP was injected into the hypothalamic supraoptic nuclei of Brattleboro rats resulting in expression of functional AVP peptide in magnocellular neurons. This was accompanied by a 100% recovery.
in water homeostasis as assessed by daily water intake, urine production, and urine osmolality lasting for at least 1 year [4].

**Mutant Leptin Receptor Rat Models**

Rat models of leptin receptor deficiency have been used to explore the restorative effect of gene therapy in the hypothalamus of these obese animals. In one study [5], leptin receptor defective Koletsky rats (fa<sup>k</sup>/fa<sup>k</sup>) were used. These animals received in the arcuate (ARC) nucleus a bilateral 0.5-μl injection containing either an adeno viral vector (Ad-lepr<sup>b</sup>) expressing the signaling isoform of the leptin receptor lepr<sup>b</sup> (2.4 × 10<sup>12</sup> pfu/ml) or an Ad vector (Ad-lacZ) expressing the β-galactosidase (β-gal) reporter gene (1.7 × 10<sup>12</sup> pfu/ml). Sixteen days postinjection, Ad-lepr<sup>b</sup> – but not Ad-lacZ-injected animals showed restored lepr<sup>b</sup> mRNA levels (which are low in control mutants) in the ARC nucleus. Restored leptin receptor expression reduced both mean daily food consumption (13%) and body weight gain (33%). It also increased hypothalamic pro-opiomelanocortin (POMC) mRNA levels (65%) while decreasing neuropeptide Y mRNA levels by 30%, relative to Ad-lacZ-injected mutants. In contrast, Ad-lepr<sup>b</sup> injection in the ARC nucleus of wild-type animals had no effect on the above parameters.

A similar experimental approach was implemented in Zucker (fa/fa) rats which are obese, hyperphagic and hyperinsulinemic as a consequence of a mutation in their leptin receptor. These animals received in the ARC nucleus a stereotaxic bilateral injection (3 µl/side; 1.28 × 10<sup>9</sup> particles) of either a recombinant adeno-associated viral (rAAV) vector expressing murine POMC (rAAV-POMC) or a rAAV expressing enhanced green fluorescent protein (rAAV-eGFP). At day 38 postinjection, the rAAV-POMC-injected animals showed a 4-fold increase in hypothalamic POMC expression and a 62% increase in melanocortin signaling (indicated by phosphorylation of the cAMP response element binding protein, CREB), relative to rAAV-eGFP-injected animals. A sustained reduction in food intake, weight gain and visceral adiposity was also observed in the experimental animals. POMC transgene delivery also increased the uncoupling of brown adipose tissue (BAT) protein. Circulating leptin, cholesterol and insulin were reduced in the rAAV-POMC-injected animals receptor [6].

Taken together these leptin receptor studies further demonstrate the suitability of the hypothalamus for the implementation of restorative gene therapy in mutant animal models.

**Aging Female Rat**

The dopaminergic (DA) neurons of the rat hypothalamus are grouped into two main areas, A<sub>12</sub> and A<sub>14</sub> [7, 8], with the DA perikarya of the A<sub>12</sub> area being located in the ARC nucleus and in the periaqueductal region [9]. The A<sub>14</sub> DA neurons are mainly located within the paraventricular (PaV) and periventricular (PeV)
nuclei, with a few scattered DA neurons in the anterior ventromedial (AVM) hypothalamic area [9, 10]. The A₁₂ area and its corresponding axon terminals constitute the tuberoinfundibular dopaminergic (TIDA) system, whereas the A₁₄ area and its fibers are known as the periventricular dopaminergic (PVDA) system. Both systems regulate prolactin (PRL) secretion by exerting a tonic inhibitory control on both PRL secretion and lactotrope proliferation [11]. In early studies, TIDA neuron function was reported to decline during aging in rats, with a marked reduction in hypothalamic, median eminence and neurointermediate lobe DA content in old (24–26 months) as compared with young (4 months) rats [12]. More significant, the rate of DA secretion into the hypophysial portal blood of aged (20–26 months) male and female rats was found to decline drastically when compared with young (2–4 months) counterparts [13, 14]. Although the above age-related alterations in hypothalamic DA secretion were ascribed to a functional decline of TIDA neurons rather than to TIDA neuron loss [12], more recent work in very old female rats (32 months) showed that at extreme ages, DA neuron loss occurs in the rat hypothalamus, particularly in the PaV nucleus [15]. The degeneration and loss of TIDA neurons during normal aging is associated, in the female rat, with progressive hyperprolactinemia [16] and the development of pituitary prolactinomas [17]. Interestingly, parkinsonian patients usually reveal functional alterations in the hypothalamo-PRL axis [18].

It should be pointed out that although a number of in vivo models have been developed for the study of the pathophysiology of Parkinson disease (PD) as well as for the assessment of new therapeutic strategies for this devastating pathology [19], they share a significant limitation namely, that the neurological lesions they study are caused by experimental manipulations rather than by aging, the only unequivocal risk factor for PD [20, 21]. In this context, the aging female rat emerges as an interesting model of spontaneous and progressive central DAergic dysfunction. Besides, the functional status of TIDA neurons can be readily and humanely monitored in the animals by measuring circulating PRL levels.

A protective effect of insulin-like growth factor-I (IGF-I) gene transfer has been reported in human DA cell cultures exposed to the toxin salsolinol [22]. In vivo, restorative IGF-I gene therapy was implemented in young (5 months) and senile (28 months) female rats, which received a single intrahypothalamic injection of $3 \times 10^9$ pfu of adenoviral vectors expressing either the reporter gene for β-gal or rat IGF-I (control and experimental group, respectively) and were sacrificed 17 days postinjection (fig. 1). In the young animals, neither vector modified serum PRL levels but in the IGF-I vector-injected senile rats a nearly full reversion of their hyperprolactinemic status was recorded. Morphometric analysis revealed a significant increase in the total number of tyrosine hydroxylase (TH)-positive cells in the hypothalamus of experimental as compared with control senile animals.
Gene Therapy in the Neuroendocrine System

These results indicate that IGF-I gene therapy in senile female rats is highly effective for reversing their hypothalamic DAergic neurodegeneration.

**In vivo Gene Therapy in the Pituitary Gland**

*Retinoblastoma Mutant Mouse*

Another type of neuroendocrine model used to implement corrective gene therapy is that based on the transfer of a gene(s) with the ability to rescue the normal phenotype of pituitary tumor cells. This approach has been implemented in mice heterozygous for the retinoblastoma (Rb) tumor suppressor gene (Rb<sup>+-</sup> mice). Such mice develop and succumb to characteristic pituitary intermediate lobe melanotrope tumors [25]. Transduction of tumor melanotrophic cells with a recombinant adenoviral vector (rAd5.R.Rb) carrying the human Rb cDNA under the control of its own promoter showed a high level of efficiency both in vitro and in vivo [26]. Furthermore, intracranial delivery of this vector to mice carrying actively growing melanotrophic tumors significantly reduced tumor growth and prolonged animal survival. Melanotrophic tumor proliferative index and apoptotic rates were markedly lowered in the rAd5.R.Rb-treated
animals, which also showed growth-inhibitory dopaminergic neuron reinnervation of melanotropic cells [26].

**Suicide Gene Therapy in Experimental Pituitary Tumors**

An adenoviral vector, RAdTK, harboring the herpes simplex type 1 thymidine kinase (HSV-1 TK) suicide gene under the control of the human CMV promoter has been used to transfer the TK gene to GH₃ and AtT₂₀ rodent pituitary cell lines. Incubation of RAdTK-treated GH₃ and AtT₂₀ cells with the prodrug ganciclovir (which after phosphorylation by viral TK becomes toxic) caused total destruction of the cultures [27]. In the same study, estrogen-induced rat prolactinomas were stereotaxically injected with the same RAdTK. Subsequent injection of the host animals with two daily i.p. doses of 25 mg ganciclovir/kg for 7 days partially succeeded in reducing AP tumor size and serum PRL levels.

**Concluding Remarks**

The implementation of experimental gene therapy in neuroendocrine models has revealed a number of advantages of this system for in vivo studies. The more relevant of these advantages is that the effectiveness and long-term duration of the treatment can be readily monitored by measuring hormone levels or other peripheral variables regulated by the neuroendocrine system. The age-related degeneration of TIDA neurons in female rats offers a unique animal model for the assessment of neuroprotective gene therapy strategies for PD. Further implementation of gene therapy strategies in neuroendocrine models may prove to be highly rewarding.

**Acknowledgements**

This work was supported in part by grants PICT13588 and PICT10663 from the (Argentine) National Agency for the Promotion of Science and Technology (ANPCyT) and grant NIH#1 R21 TW006665 from the Fogarty International Center and the National Institute on Aging (USA) to R.G.G. R.G.G. and O.A.B. are Research Career scientists of the Argentine Research Council (CONICET). C.B.H. is a doctoral fellowship recipient from CONICET, P.C.R. and G.R.M. are doctoral fellowship recipients from ANPCyT and M.J.B. is a postdoctoral fellowship recipient from NIH.

**References**


Rodolfo G. Goya
INIBIOLP, Faculty of Medicine, UNLP, CC 455
1900 La Plata (Argentina)
Tel. +54 221 425 6735, Fax +54 221 425 0924/425 8988
E-Mail goya@isis.unlp.edu.ar/rgoya@netverk.com.ar